Imunon Posts $2.8M Q2 Loss, $6.9M Cash; Ovarian Cancer Trial Enrollment Ahead of Plan
IMNN is trading near its 52-week low of $1.47 (15% above the low) on light trading volume (0.3× avg).
Summary
Imunon reported Q2 2026 financials: $6.9 million in cash and a $2.8 million net loss. The net loss widened slightly due to rising R&D costs. The cash position improved from $4.8 million at the end of Q1, reflecting the $10 million financing closed in June. Enrollment in the pivotal Phase 3 OVATION 3 trial for IMNN-001 in advanced ovarian cancer is exceeding forecasts, with completion expected by the first half of 2029. The company also announced an R&D Day on September 23, 2026, to highlight clinical data. The cash runway remains tight, but the trial momentum and recent positive Phase 2 MRD data keep the story alive.
At the time of this announcement, IMNN was trading at $1.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.8M. The 52-week trading range was $1.47 to $7.28. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.